Related Experiment Video
Updated: Mar 14, 2026
Immunohistochemical Visualization of Hippocampal Neuron Activity After Spatial Learning in a Mouse Model of Neurodevelopmental Disorders
Published on: May 12, 2015
Differential expression of miR-184 in temporal lobe epilepsy patients with and without hippocampal sclerosis -
Bénédicte Danis1, Marijke van Rikxoort2, Anita Kretschmann2
1UCB Pharma S. A., Chemin du Foriest, B - 1420 Braine-l'Alleud, Belgium.
Abstract:
Epilepsy is one of the most common neurological disorders characterized by recurrent seizures due to neuronal hyperexcitability. Here we compared miRNA expression patterns in mesial temporal lobe epilepsy with and without hippocampal sclerosis (mTLE + HS and mTLE -HS) to investigate the regulatory mechanisms differentiating both patient groups. Whole genome miRNA sequencing in surgically resected hippocampi did not reveal obvious differences in expression profiles between the two groups of patients. However, one microRNA (miR-184) was significantly dysregulated, which was confirmed by qPCR. We observed that overexpression of miR-184 inhibited cytokine release after LPS stimulation in primary microglial cells, while it did not affect the viability of murine primary neurons and primary astrocytes. Pathway analysis revealed that miR-184 is potentially involved in the regulation of inflammatory signal transduction and apoptosis. Dysregulation of some the potential miR-184 target genes was confirmed by qPCR and 3'UTR luciferase reporter assay. The reduced expression of miR-184 observed in patients with mTLE + HS together with its anti-inflammatory effects indicate that miR-184 might be involved in the modulation of inflammatory processes associated with hippocampal sclerosis which warrants further studies elucidating the role of miR-184 in the pathophysiology of mTLE.
Insights
MicroRNA-184 (miR-184) dysregulation is linked to mesial temporal lobe epilepsy with hippocampal sclerosis. This microRNA shows anti-inflammatory effects, suggesting a role in epilepsy-associated inflammation.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Epilepsy is a common neurological disorder marked by seizures from neuronal hyperexcitability.
- Mesial temporal lobe epilepsy (mTLE) is a frequent epilepsy subtype, often associated with hippocampal sclerosis (HS).
- Understanding molecular differences between mTLE with HS (mTLE+HS) and without HS (mTLE-HS) is crucial for elucidating disease mechanisms.
Purpose of the Study:
- To compare microRNA (miRNA) expression profiles in mTLE+HS and mTLE-HS patients.
- To investigate the role of dysregulated miRNAs in the pathophysiology of mTLE, particularly concerning hippocampal sclerosis.
- To explore the functional impact of identified miRNAs on inflammatory pathways and neuronal/glial cell function.
Main Methods:
- Whole genome miRNA sequencing of surgically resected hippocampi from mTLE+HS and mTLE-HS patients.
- Quantitative real-time PCR (qPCR) to validate miRNA expression and target gene dysregulation.
- In vitro studies using primary microglial cells, neurons, and astrocytes to assess miR-184 function.
- Pathway analysis to predict miR-184's regulatory roles.
- 3'UTR luciferase reporter assay to confirm miRNA-target interactions.
Main Results:
- No widespread miRNA expression differences were found between mTLE+HS and mTLE-HS groups.
- MicroRNA-184 (miR-184) was significantly dysregulated in mTLE+HS patients.
- Overexpression of miR-184 inhibited cytokine release in LPS-stimulated microglial cells but did not affect neuronal or astrocyte viability.
- Pathway analysis suggested miR-184 involvement in inflammatory signal transduction and apoptosis.
- qPCR and luciferase assays confirmed dysregulation of predicted miR-184 target genes.
Conclusions:
- Reduced miR-184 expression in mTLE+HS patients correlates with its anti-inflammatory effects.
- miR-184 may play a role in modulating inflammatory processes associated with hippocampal sclerosis in mTLE.
- Further research is warranted to fully elucidate the function of miR-184 in mTLE pathophysiology.
